Clinical trialCLINICALTRIALSMar 26
Trial Results Posted: Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E) (NCT06303167)
Researchers tested a cancer drug called osimertinib (AZD9291) in 19 patients with advanced cancers that have specific genetic changes in a gene called EGFR. The drug works by blocking a mutated protein that helps cancer cells grow. This trial is now complete and results have been posted.
WHY IT MATTERSThis trial provides evidence that osimertinib may work against cancers with EGFR mutations across different cancer types, potentially offering a treatment option for patients whose tumors have this specific genetic change.